MARKET

NCNA

NCNA

Nucana
NASDAQ
1.400
-0.080
-5.41%
After Hours: 1.400 0 0.00% 19:28 03/27 EDT
OPEN
1.490
PREV CLOSE
1.480
HIGH
1.520
LOW
1.390
VOLUME
57.40K
TURNOVER
--
52 WEEK HIGH
268.00
52 WEEK LOW
1.390
MARKET CAP
5.83M
P/E (TTM)
-0.0796
1D
5D
1M
3M
1Y
5Y
1D
NuCana files Form 3 initial beneficial ownership statement for Head of Translational Medicine David Harrison
Reuters · 3d ago
Weekly Report: what happened at NCNA last week (0316-0320)?
Weekly Report · 5d ago
NuCana plc director Martin C.B. Mellish files initial beneficial ownership statement
Reuters · 03/20 20:14
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 03/20 12:05
Unusual Machines, NuCana, Navigator Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 03/20 12:02
NuCana plc files Form 3 initial beneficial ownership statement for Chief Medical Officer Jeffrey D. Bloss
Reuters · 03/19 21:53
NuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029
TipRanks · 03/19 20:27
UK's NuCana Q4 net loss widens 
Reuters · 03/19 20:25
More
About NCNA
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.

Webull offers NuCana PLC (ADR) stock information, including NASDAQ: NCNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NCNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NCNA stock methods without spending real money on the virtual paper trading platform.